株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ウイルスベクター・プラスミドDNA:各種技術および世界の市場

Viral Vector and Plasmid DNA: Technologies and Global Markets

発行 BCC Research 商品コード 911582
出版日 ページ情報 英文 133 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
ウイルスベクター・プラスミドDNA:各種技術および世界の市場 Viral Vector and Plasmid DNA: Technologies and Global Markets
出版日: 2019年09月18日 ページ情報: 英文 133 Pages
概要

世界のウイルスベクター・プラスミドDNAの市場は予測期間中18.0%のCAGR (複合年間成長率) で推移し、2019年の5億ドルから、2024年には11億ドルの規模に成長すると予測されています。

当レポートでは、世界のウイルスベクター・プラスミドDNAの市場を調査し、市場および技術の定義・概要、市場の発展の経緯、市場成長への各種影響因子の分析、製品タイプ・エンドユーザー・用途・地域/主要国別の分析・予測、特許動向、市場機会の分析、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場・技術の背景

  • 遺伝子治療
  • プラスミド製造
  • 市場動向
  • 市場力学

第4章 市場分析・予測:製品タイプ別

  • プラスミドDNA
  • ウイルスベクター

第5章 市場分析・予測:エンドユーザー別

  • 研究機関
  • 医薬品・バイオ医薬品企業

第6章 市場分析・予測:用途別

  • 感染症
  • CVD
  • その他

第7章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スぺイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他
  • 中東・アフリカ
  • ラテンアメリカ

第8章 特許概要・新規開発

  • 新製品・技術
  • 特許分析

第9章 市場機会の分析

  • 主要サプライヤー・製造業者:位置付け・戦略
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Lonza Group Ltd.
    • GenScript Biotech Corp.
    • Pfizer Inc.
  • R&Dプログラム
  • パイプライン分析
  • 創薬

第10章 企業プロファイル

図表

List of Tables

  • Summary Table: Global Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
    • Table 1: Types of Gene Therapy
    • Table 2: Clinical Trials for Viral Vector-Mediated Gene Therapy in the U.S., 2018 and 2019
    • Table 3: Partnerships for Viral Vector-Mediated Gene Therapy
    • Table 4: Global Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
    • Table 5: Characteristics of Plasmid DNA Isolation Technology, 2019
    • Table 6: Global Market for Plasmid DNA, by Region, Through 2024
    • Table 7: Global Market for Viral Vector, by Region, Through 2024
    • Table 8: Global Market for Viral Vector and Plasmid DNA, by End User, Through 2024
    • Table 9: Global Market for Viral Vector and Plasmid DNA in Research Institutes, by Region, Through 2024
    • Table 10: Global Market for Viral Vector and Plasmid DNA in Pharmaceutical and Biopharmaceutical Companies, by Region, Through 2024
    • Table 11: Global Market for Viral Vector and Plasmid DNA, by Application, Through 2024
    • Table 12: Viral Vectors Used in Gene Therapy
    • Table 13: Global Market Viral Vector and Plasmid DNA in Cancer, by Region, Through 2024
    • Table 14: Pipeline Products for Cancer Gene Therapy, 2018 and 2019
    • Table 15: Global Market for Viral Vector and Plasmid DNA in Infectious Diseases, by Region, Through 2024
    • Table 16: Gene Transfer Vectors Used in Heart Gene Therapy
    • Table 17: Global Market for Viral Vector and Plasmid DNA in CVD, by Region, Through 2024
    • Table 18: Global Market for Viral Vector and Plasmid DNA in Other Applications, by Region, Through 2024
    • Table 19: Global Market for Viral Vector and Plasmid DNA, by Region, Through 2024
    • Table 20: New Cases of Tuberculosis, by Country, 2017
    • Table 21: Ebola Virus Disease Outbreaks in Chronological Order, 2012-2019
    • Table 22: North American Market for Viral Vector and Plasmid DNA, by Country, Through 2024
    • Table 23: North American Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
    • Table 24: North American Market for Viral Vector and Plasmid DNA, by Application, Through 2024
    • Table 25: North American Market for Viral Vector and Plasmid DNA, by End User, Through 2024
    • Table 26: Research Institutes for Gene Therapy in the U.S.
    • Table 27: New Cancer Cases in the U.S., by Gender, 2019
    • Table 28: New Cancer Cases Diagnosed in Canada, 2019
    • Table 29: European Market for Viral Vector and Plasmid DNA, by Country, Through 2024
    • Table 30: European Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
    • Table 31: European Market for Viral Vector and Plasmid DNA, by Application, Through 2024
    • Table 32: European Market for Viral Vector and Plasmid DNA, by End User, Through 2024
    • Table 33: New Cancer Cases and Mortalities in France, 2018
    • Table 34: New Cancer Cases in European Countries, 2018
    • Table 35: Asia-Pacific Market for Viral Vector and Plasmid DNA, by Country, Through 2024
    • Table 36: Asia-Pacific Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
    • Table 37: Asia-Pacific Market for Viral Vector and Plasmid DNA, by Application, Through 2024
    • Table 38: Asia-Pacific Market for Viral Vector and Plasmid DNA, by End User, Through 2024
    • Table 39: New Cancer Cases and Mortalities in China, 2018
    • Table 40: New Cancer Cases in Asia-Pacific Countries, 2018
    • Table 41: MEA Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
    • Table 42: MEA Market for Viral Vector and Plasmid DNA, by Application, Through 2024
    • Table 43: MEA Market for Viral Vector and Plasmid DNA, by End User, Through 2024
    • Table 44: Latin American Market for Viral Vector and Plasmid DNA, by Product Type, Through 2024
    • Table 45: Latin American Market for Viral Vector and Plasmid DNA, by Application, Through 2024
    • Table 46: Latin American Market for Viral Vector and Plasmid DNA, by End User, Through 2024
    • Table 47: New Product Developments, 2017-2019
    • Table 48: Number of Patents Grants, by Categories in Different Countries, January 2017-July 2019
    • Table 49: Number of Patents, by Key Players in the U.S., Europe and Japan, January 2017-July 2019
    • Table 50: Total Number of Analyzed Patents, January 2017-July 2019
    • Table 51: Key Financial Statistics of Thermo Fisher Scientific, Inc., 2017 and 2018
    • Table 52: Key Financial Statistics of Merck KGaA, 2017 and 2018
    • Table 53: Key Financial Statistics of Lonza Group Ltd., 2017 and 2018
    • Table 54: Key Financial Statistics of GenScript Biotech Corp., 2017 and 2018
    • Table 55: Key Financial Statistics of Pfizer Inc., 2017 and 2018
    • Table 56: Viral Vector-Mediated Gene Therapies in Development, 2018 and 2019
    • Table 57: Viral Vector-Mediated Gene Therapy Clinical Trials Database, 2018

List of Figures

  • Summary Figure: Global Market for Viral Vector and Plasmid DNA, by Product Type, 2018-2024
    • Figure 1: Processes of Gene Therapy Research
    • Figure 2: Processes of Gene Therapy Development
    • Figure 3: Typical Production Process Flow for Viral Vectors
    • Figure 4: Most Common Cancer Types, Global Cases, 2018
    • Figure 5: Progression of cGMP Compliance for Drug Development
    • Figure 6: Shares of New Cancer Cases, Globally, by Cancer Type, 2018
    • Figure 7: Shares of New Cancer Cases in North America, by Cancer Type, 2018
    • Figure 8: Shares of New Cancer Cases in Europe, by Cancer Type, 2018
    • Figure 9: Prevalence of Cancer in U.K., 2011-2017
    • Figure 10: Prevalence of Cancer in Germany, by Cancer Type, 2014-2016
    • Figure 11: Colorectal Cancer Incidences in Italy, 2015 and 2016
    • Figure 12: Prevalence of Colorectal Cancer in Spain, 2011-2016
    • Figure 13: Shares of New Cancer Cases in Asia, by Cancer Type, 2018
    • Figure 14: Shares of New Cancer Cases in Oceania, by Cancer Type, 2018
    • Figure 15: Shares of New Cancer Cases in Japan, by Cancer Type, 2018
    • Figure 16: Shares of New Cancer Cases in India, by Cancer Type, 2018
    • Figure 17: Pharmaceutical Expenditures per Capita, by Country, 2015
    • Figure 18: Shares of New Cancer Cases in MEA, by Cancer Type, 2018
    • Figure 19: New HIV Cases and Mortalities in MEA, 2017
    • Figure 20: Shares of New Cancer Cases in Latin America and the Caribbean, by Cancer Type, 2018
目次
Product Code: BIO192A

Report Highlights:

The global viral vector and plasmid DNA technologies market should grow from $500 million in 2019 to over $1.1 billion by 2024 with a compound annual growth rate (CAGR) of 18.0% during the period, 2019-2024.

The global viral vector-based therapeutics market should grow from $350 million in 2019 to $805 million by 2024 with a CAGR of 18.1% during the period, 2019-2024.

The global plasmid DNA technologies market should grow from $150 million in 2019 to $340 million by 2024 with a CAGR of 17.8% during the period, 2019-2024.

Report Scope:

The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market, along with detailed profiles of key market players that includes revenue product portfolio and recent activities. The report analyzes trends and dynamics, including drivers, limitations and challenges and opportunities. The report discusses strategies adopted by emerging market players with recommendations for the new market entrants. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and exports of the goods and services to the original equipment manufacturer. Organizations, distributors and exporters should find the information about market development and trends useful.

The study segments the market on the basis of product type, applications and end-use. Geographical market analysis is provided for all the major segments. The report offers country level analysis of markets to provide better understanding of the major segments.

Report Includes:

  • 44 data tables and 14 additional tables
  • An in-depth assessment of the global viral vector and plasmid DNA technologies market within the life sciences sectors
  • Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • The latest information on key technical advances in different viral vector and plasmid DNA technologies, and the extent of adoption by commercial customers and regulatory authorities
  • A proprietary analysis of the market including an easy-to-understand graphical representation of facts, innovations in pharmaceutical and biotechnology companies, and R&D activities in viral vector-based treatments and Plasmid DNA vaccines
  • Key strategies adopted by major players in the market and the impact of new technological developments in developed and emerging markets
  • Assessment of the suppliers' landscape on the basis of companies best positioned to meet this ever evolving demand
  • Comprehensive company profiles of market leading players, including Aldevron LLC, Merck KGaA, Lonza Group Ltd., GenScript Biotech Corp., Pfizer Inc., and Thermo Fisher Scientific, Inc.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Gene Therapy
  • Plasmid Production
  • Description of Market Trends
  • Market Dynamics

Chapter 4: Market Breakdown by Product Type

  • Plasmid DNA
  • Viral Vector

Chapter 5: Market Breakdown by End User

  • Research Institutes
  • Pharmaceutical and Biopharmaceutical Companies

Chapter 6: Market Breakdown by Application

  • Cancer
  • Infectious Diseases
  • CVD
  • Other Applications

Chapter 7: Market Breakdown by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
  • Middle East and Africa (MEA)
  • Latin America

Chapter 8: Patent Review/New Developments

  • New Products and Technologies
  • Patent Analysis

Chapter 9: Analysis of Market Opportunities

  • Key Suppliers and Manufacturers: Positioning and Strategy
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Lonza Group Ltd.
  • GenScript Biotech Corp.
  • Pfizer Inc.
  • R&D Programs
  • Pipeline Analysis
  • Discovery

Chapter 10: Company Profiles

  • ABEONA THERAPEUTICS INC.
  • AKRON BIOTECH
  • ALDEVRON, LLC
  • AMARNA THERAPEUTICS B.V.
  • APPLIED BIOLOGICAL MATERIALS INC.
  • AUDENTES THERAPEUTICS INC.
  • BATAVIA BIOSCIENCES B.V.
  • BAYER AG
  • BIOMARIN PHARMACEUTICAL INC.
  • BIONTECH IMFS GMBH
  • BLUEBIRD BIO INC.
  • CELLECTA INC.
  • COBRA BIOLOGICS LTD.
  • CRISPR THERAPEUTICS AG
  • DELPHI GENETICS S.A.
  • FINVECTOR VISION THERAPIES OY
  • FUJIFILM DIOSYNTH BIOTECHNOLOGIES INC.
  • GENSCRIPT BIOTECH CORP.
  • GENEZEN LABORATORIES
  • GENERAL ELECTRIC CO.
  • IMMUSOFT CORP.
  • LAKEPHARMA INC.
  • LONZA GROUP LTD.
  • LYSOGENE SA
  • MAXCYTE INC.
  • MERCK KGAA
  • NOVARTIS INTERNATIONAL AG
  • NOVASEP HOLDING SAS
  • ORCHARD THERAPEUTICS PLC
  • ORIGENE TECHNOLOGIES INC.
  • OXFORD BIOMEDICA PLC
  • OXFORD GENETICS LTD.
  • PFIZER INC.
  • PLASMIDFACTORY GMBH & CO. KG
  • POSEIDA THERAPEUTICS INC.
  • PROMEGA CORP.
  • PSIOXUS THERAPEUTICS LTD.
  • REGENXBIO INC.
  • REPLIGEN CORP.
  • ROCKET PHARMACEUTICALS, LTD.
  • SANGAMO THERAPEUTICS INC.
  • SIRION-BIOTECH GMBH
  • SIGNAGEN LABORATORIES
  • SPARK THERAPEUTICS INC.
  • THERMO FISHER SCIENTIFIC, INC.
  • ULTRAGENYX PHARMACEUTICAL INC.
  • UNIQURE N.V.
  • VGXI INC.
  • VIGENE BIOSCIENCES INC.
  • WAISMAN BIOMANUFACTURING
  • YPOSKESI INC.
Back to Top